Phase II study of nivolumab in Japanese patients with relapsed or refractory Hodgkin lymphoma previously treated with brentuximab vedotin (ONO-4538-15): An interim analysis.

被引：3
|
作者：
Hatake, Kiyohiko
Kinoshita, Tomohiro
Fukuhara, Noriko
Choi, Ilseung
Taniwaki, Masafumi
Ando, Kiyoshi
Maruyama, Dai
Terui, Yasuhito
Higuchi, Yusuke
Onishi, Yasushi
Abe, Yasunobu
Kobayashi, Tsutomu
Shirasugi, Yukari
Tobinai, Kensei
机构：
[1] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Hematol & Oncol, Tokyo, Japan
[2] Aichi Canc Ctr, Dept Hematol & Cell Therapy, Nagoya, Aichi, Japan
[3] Tohoku Univ, Grad Sch Med, Dept Hematol & Rheumatol, Sendai, Miyagi, Japan
[4] Natl Hosp Org Kyushu Canc Ctr, Dept Hematol, Fukuoka, Japan
[5] Kyoto Prefectural Univ Med, Univ Hosp, Div Hematol & Oncol, Kyoto, Japan
[6] Tokai Univ, Dept Hematol & Oncol, Isehara, Kanagawa, Japan
[7] Natl Canc Ctr, Dept Hematol, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e19018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19018
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Brentuximab Vedotin and Pembrolizumab Combination in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Single-Centre Retrospective Analysis
    Massaro, Fulvio
    Meuleman, Nathalie
    Bron, Dominique
    Vercruyssen, Marie
    Maerevoet, Marie
    CANCERS, 2022, 14 (04)
  • [32] Treatment patterns, health care resource utilization, and costs in patients with relapsed/refractory Hodgkin lymphoma treated with brentuximab vedotin
    Shao, Changxia
    Liu, Jinan
    Zhou, Wei
    Raut, Monika K.
    Monberg, Matthew
    Cao, Xiting
    Ricart, Alejandro D.
    Balakumaran, Arun
    LEUKEMIA & LYMPHOMA, 2019, 60 (04) : 947 - 954
  • [33] Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP
    Driessen, Julia
    Kersten, Marie Jose
    Visser, Lydia
    van den Berg, Anke
    Tonino, Sanne H.
    Zijlstra, Josee M.
    Lugtenburg, Pieternella J.
    Morschhauser, Franck
    Hutchings, Martin
    Amorim, Sandy
    Gastinne, Thomas
    Nijland, Marcel
    Zwezerijnen, Gerben J. C.
    Boellaard, Ronald
    de Vet, Henrica C. W.
    Arens, Anne I. J.
    Valkema, Roelf
    Liu, Roberto D. K.
    Drees, Esther E. E.
    de Jong, Daphne
    Plattel, Wouter J.
    Diepstra, Arjan
    LEUKEMIA, 2022, 36 (12) : 2853 - 2862
  • [34] Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP
    Julia Driessen
    Marie José Kersten
    Lydia Visser
    Anke van den Berg
    Sanne H. Tonino
    Josée M. Zijlstra
    Pieternella J. Lugtenburg
    Franck Morschhauser
    Martin Hutchings
    Sandy Amorim
    Thomas Gastinne
    Marcel Nijland
    Gerben J. C. Zwezerijnen
    Ronald Boellaard
    Henrica C. W. de Vet
    Anne I. J. Arens
    Roelf Valkema
    Roberto D. K. Liu
    Esther E. E. Drees
    Daphne de Jong
    Wouter J. Plattel
    Arjan Diepstra
    Leukemia, 2022, 36 : 2853 - 2862
  • [35] Treatment patterns and costs of care for patients with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin in the United States: A retrospective cohort study
    Szabo, Shelagh M.
    Hirji, Ishan
    Johnston, Karissa M.
    Juarez-Garcia, Ariadna
    Connors, Joseph M.
    PLOS ONE, 2017, 12 (10):
  • [36] PHASE 1/2 STUDY OF BRENTUXIMAB VEDOTIN IN PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA OR SYSTEMIC ANAPLASTIC LARGE-CELL LYMPHOMA: INTERIM PHASE 1 SAFETY AND PHARMACOKINETIC DATA
    Locatelli, F.
    Gore, L.
    Mauz-Koerholz, C.
    Rosolen, A.
    Landman-Parker, J.
    de Toledo, J.
    Beishuizen, A.
    Fasanmade, A.
    Wang, J.
    Fingert, H.
    Labotka, R.
    Neville, K.
    HAEMATOLOGICA, 2013, 98 : 68 - 68
  • [37] A pilot phase II study with brentuximab vedotin followed by ABVD in patients with previously untreated Hodgkin lymphoma: A preliminary report.
    Federico, Massimo
    Pesce, Emanuela Anna
    Merli, Francesco
    Luminari, Stefano
    Chauvie, Stephane
    Pellegrini, Cinzia
    Marcheselli, Luigi
    Capodanno, Isabella
    Ilariucci, Fiorella
    Salati, Massimiliano
    Argnani, Lisa
    Zinzani, Pier Luigi
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [38] A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results
    Jacobsen, Eric D.
    Advani, Ranjana H.
    Oki, Yasuhiro
    Sharman, Jeff
    Horwitz, Steven M.
    Forero-Torres, Andres
    O'Connor, Owen A.
    Shustov, Andrei R.
    Siddiqi, Tanya
    Grove, Laurie E.
    Bartlett, Nancy L.
    BLOOD, 2012, 120 (21)
  • [39] TARC Predicts PET-Normalization and Event Free Survival in Relapsed/Refractory Hodgkin Lymphoma Patients Treated With Brentuximab Vedotin
    Chen, Robert W.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (02) : 10 - 12
  • [40] Phase 2 Study of Frontline Brentuximab Vedotin Plus Nivolumab in Patients With Hodgkin Lymphoma Aged ≥60 Years
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02) : 8 - 9
12345